Vivos Therapeutics plans rights offering to distribute subscription rights to shareholders.

Vivos Therapeutics announced its intent to file a registration statement for a proposed rights offering that would distribute transferable subscription rights to shareholders, with an exercise price of at least $1.25 per share or 20% above market price. The offering structure includes a nine-month exercise period and a subsequent 'exploding' right feature, subject to SEC approval and other regulatory conditions.